These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36315597)

  • 1. Prophylactic low-dose, bi-weekly benznidazole treatment fails to prevent Trypanosoma cruzi infection in dogs under intense transmission pressure.
    Bustamante JM; Padilla AM; White B; Auckland LD; Busselman RE; Collins S; Malcolm EL; Wilson BF; Saunders AB; Hamer SA; Tarleton RL
    PLoS Negl Trop Dis; 2022 Oct; 16(10):e0010688. PubMed ID: 36315597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency Variation and Dose Modification of Benznidazole Administration for the Treatment of Trypanosoma cruzi Infection in Mice, Dogs, and Nonhuman Primates.
    Bustamante JM; White BE; Wilkerson GK; Hodo CL; Auckland LD; Wang W; McCain S; Hamer SA; Saunders AB; Tarleton RL
    Antimicrob Agents Chemother; 2023 May; 67(5):e0013223. PubMed ID: 37039666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection.
    Rial MS; Scalise ML; López Alarcón M; Esteva MI; Búa J; Benatar AF; Prado NG; Riarte AR; Fichera LE
    Parasitology; 2019 Mar; 146(3):305-313. PubMed ID: 30301480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benznidazole in Cerebrospinal Fluid: a Case Series of Chagas Disease Meningoencephalitis in HIV-Positive Patients.
    Fernández ML; Marson ME; Mastrantonio GE; Corti MA; Fleitas U; Lloveras SC; Lista N; Priarone MM; Domínguez C; Garcia-Bournissen F
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trypanosoma cruzi: Does the intake of nanoencapsulated benznidazole control acute infections?
    Dutra da Silva A; Fracasso M; Bottari NB; Gundel S; Ourique AF; Assmann CE; Ferreira DASP; Castro MFV; Reichert KP; de Souza LAF; da Veiga ML; da Rocha MIUM; Monteiro SG; Morsch VM; Chitolina Schetinger MR; da Silva AS
    Exp Parasitol; 2023 Jun; 249():108520. PubMed ID: 37001581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
    Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
    Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency variation and dose modification of benznidazole administration for the treatment of
    Bustamante JM; White BE; Wilkerson GK; Hodo CL; Auckland LD; Wang W; McCain S; Hamer SA; Saunders AB; Tarleton RL
    bioRxiv; 2023 Feb; ():. PubMed ID: 36778432
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.
    de Jesus SM; Pinto L; Moreira FL; Nardotto GHB; Cristofoletti R; Perin L; Fonseca KDS; Barbêdo P; Bandeira LC; Vieira PMA; Carneiro CM
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains.
    Veloso VM; Carneiro CM; Toledo MJ; Lana M; Chiari E; Tafuri WL; Bahia MT
    Mem Inst Oswaldo Cruz; 2001 Oct; 96(7):1005-11. PubMed ID: 11685270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.
    Li X; Yi S; Scariot DB; Martinez SJ; Falk BA; Olson CL; Romano PS; Scott EA; Engman DM
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33986194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial scars correlate with eletrocardiographic changes in chronic Trypanosoma cruzi infection for dogs treated with Benznidazole.
    Caldas IS; da Matta Guedes PM; dos Santos FM; de Figueiredo Diniz L; Martins TA; da Silva do Nascimento AF; Azevedo MA; de Lima WG; Neto RM; Torres RM; Talvani A; Bahia MT
    Trop Med Int Health; 2013 Jan; 18(1):75-84. PubMed ID: 23107306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dehydroepiandrosterone-sulfate (DHEA-S) and benznidazole treatments during acute infection of two different Trypanosoma cruzi strains.
    Santos CD; Loria RM; Oliveira LG; Kuehn CC; Toldo MP; Albuquerque S; do Prado JC
    Immunobiology; 2010 Dec; 215(12):980-6. PubMed ID: 20163889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations.
    Leite DI; Fontes FV; Bastos MM; Hoelz LVB; Bianco MDCAD; de Oliveira AP; da Silva PB; da Silva CF; Batista DDGJ; da Gama ANS; Peres RB; Villar JDF; Soeiro MNC; Boechat N
    Chem Biol Drug Des; 2018 Sep; 92(3):1670-1682. PubMed ID: 29745048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice.
    Dzul-Huchim VM; Ramirez-Sierra MJ; Martinez-Vega PP; Rosado-Vallado ME; Arana-Argaez VE; Ortega-Lopez J; Gusovsky F; Dumonteil E; Cruz-Chan JV; Hotez P; Bottazzi ME; Villanueva-Lizama LE
    PLoS Negl Trop Dis; 2022 Sep; 16(9):e0010258. PubMed ID: 36095001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chagas cardiomyopathy: The potential effect of benznidazole treatment on diastolic dysfunction and cardiac damage in dogs chronically infected with Trypanosoma cruzi.
    Santos FM; Mazzeti AL; Caldas S; Gonçalves KR; Lima WG; Torres RM; Bahia MT
    Acta Trop; 2016 Sep; 161():44-54. PubMed ID: 27215760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice.
    Perin L; Moreira da Silva R; Fonseca KD; Cardoso JM; Mathias FA; Reis LE; Molina I; Correa-Oliveira R; Vieira PM; Carneiro CM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.